Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Total Current Liabilities (2016 - 2025)

Editas Medicine (EDIT) has disclosed Total Current Liabilities for 11 consecutive years, with $61.8 million as the latest value for Q3 2025.

  • Quarterly Total Current Liabilities fell 14.62% to $61.8 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $61.8 million through Sep 2025, down 14.62% year-over-year, with the annual reading at $77.2 million for FY2024, 22.16% up from the prior year.
  • Total Current Liabilities for Q3 2025 was $61.8 million at Editas Medicine, down from $65.9 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $77.2 million in Q4 2024, with the low at $36.4 million in Q2 2022.
  • Average Total Current Liabilities over 5 years is $59.4 million, with a median of $61.8 million recorded in 2025.
  • The sharpest move saw Total Current Liabilities plummeted 44.83% in 2022, then soared 56.58% in 2023.
  • Over 5 years, Total Current Liabilities stood at $46.9 million in 2021, then increased by 28.21% to $60.1 million in 2022, then grew by 5.17% to $63.2 million in 2023, then increased by 22.16% to $77.2 million in 2024, then fell by 20.01% to $61.8 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $61.8 million, $65.9 million, and $73.1 million for Q3 2025, Q2 2025, and Q1 2025 respectively.